Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 13/20 | 0.54 |
| ▸ | CDK2 | P24941 | 13/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909472 | 0.83 | CCNA2 (0.57) | CCNA2CDK2MEN1KMT2ACA1 | |
| SCHEMBL4915371 | 0.82 | MAPT (0.58) | CCNA2CDK2MEN1KMT2A | |
| SCHEMBL27529140 | 0.80 | CCNA2 (0.68) | CCNA2CDK2MEN1KMT2ACA1 | |
| SCHEMBL4914636 | 0.75 | MEN1 (0.53) | CCNA2CDK2MEN1KMT2ACA1 | |
| SCHEMBL28355853 | 0.73 | CCNA2 (0.56) | CCNA2CDK2MEN1KMT2ACA1 | |
| SCHEMBL10347933 | 0.72 | CA2 (0.57) | KMT2ACA1CA2CA9CA12 | |
| SCHEMBL13675233 | 0.69 | CCNA2 (0.82) | CCNA2CDK2 | |
| SCHEMBL6190659 | 0.69 | CCNA2 (0.62) | CCNA2CDK2MEN1KMT2ACA1 | |
| SCHEMBL6188285 | 0.69 | CCNA2 (0.78) | CCNA2CDK2 | |
| SCHEMBL9789038 | 0.68 | CA1 (0.52) | CCNA2CDK2MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | claimed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | claimed |
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007121154-A2 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293785-A1 | SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | CCNA2 1496/4885CDK2 89/4885MEN1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.